The study results represent the first human data from Apogee, which last year became one of the rare preclinical biopharmaceutical companies to succeed in a tough market for initial public offerings. After launching in late 2022, Apogee raised $300 million in an IPO in July 2023.
Apogee claims APG777 has the potential to be the best drug among a group of monoclonal antibodies that target a cytokine called IL-13 and are designed to compete with the blockbuster medicine Dupixent developed by Sanofi and Regeneron.
